Search

Antonella Antignani

from Potomac, MD
Age ~53
Get Report
Connected to:
Dario Antignano, 37Eileen M Antignano, 69Joseph M Antignani, 66Lawrence D Antignac, 65Flora F Antigo, 92Carlos J Antigua, 53Jobelkys J Antigua, 53John Antigua, 30Luis Antigua, 44Macarthur Antigua, 50

Antonella Antignani Phones & Addresses

  • 11801 Rockville Pike, Rockville, MD 20852 (301) 230-2819
  • Potomac, MD
  • Chevy Chase, MD
  • Washington, DC
  • 11801 Rockville Pike APT 1513, Rockville, MD 20852 (301) 230-2819

Work

Position: Professional/Technical

Education

Degree: High school graduate or higher

Publications

Us Patents

Methods And Compositions For Inhibiting Cell Death Or Enhacing Cell Proliferation

View page
US Patent:
20100317577, Dec 16, 2010
Filed:
Sep 8, 2006
Appl. No.:
11/991692
Inventors:
Richard J Youle - Chevy Chase MD, US
Antonella Antignani - North Bethesda MD, US
Assignee:
Department of Health and Human Services - Rockville MD
International Classification:
A61K 38/18
C07K 14/535
C07K 7/06
C07K 7/08
C07H 21/04
C12N 15/63
C12N 5/071
G01N 33/53
A61P 25/28
US Classification:
514 76, 530350, 530324, 530327, 530326, 536 235, 4353201, 435325, 435375, 435 721
Abstract:
The present invention provides compositions and methods that enhance cell survival. Such compositions feature chimeric polypeptides that include at least a GM-CSF receptor ligand and an anti-apoptotic moiety (e.g., a Bcl-2 protein family member). In one embodiment, the chimeric polypeptide is a GM-CSF-Bcl-xL chimeric polypeptide. The invention further includes methods of using chimeric polypeptides to enhance cell survival or inhibit cell death in a cell at risk of cell death.

Monoclonal Antibodies That Bind Egfrviii And Their Use

View page
US Patent:
20220380474, Dec 1, 2022
Filed:
Jul 1, 2020
Appl. No.:
17/623370
Inventors:
- Bethesda MD, US
Eric Chun Hei Ho - Rockville MD, US
Antonella Antignani - Potomac MD, US
Robert Joseph Sarnovsky - Phoenix MD, US
Assignee:
THE UNITED STATES OF AMERICA, as represented by the Secretary, Department of Health and Human Servic - Bethesda MD
International Classification:
C07K 16/28
C07K 14/21
Abstract:
Disclosed are monoclonal antibodies and antigen binding fragments that specifically bind epidermal growth factor receptor (EGFR) variant (v) III, conjugates thereof, and chimeric antigen receptors. Nucleic acid molecules encoding the heavy and light chain domains of the antibodies, and the chimeric antigen receptors (CARs), are also disclosed, as are host cells expressing the nucleic acid molecules. In addition, disclosed is the use of these monoclonal antibodies, antigen binding fragments, conjugates, and T cells expressing the CARs, such as for the treatment of a tumor expressing EGFRvIII. Also disclosed are methods for detecting a tumor that expresses EGFRvIII.
Control profile
Antonella Antignani from Potomac, MD, age ~53 Get Report